SCHEMBL26675328

SCHEMBL26675328

Cc1cccc(C(=O)n2nc(N)c3ccc(C4CC4)nc32)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ HTT P42858 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ TP53 P04637 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ ELANE P08246 1/20 0.37
▸ FNTA P49354 2/20 0.36
▸ FNTB P49356 2/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ TTR P02766 1/20 0.36
▸ CTDSP1 Q9GZU7 2/20 0.35
▸ DUSP3 P51452 1/20 0.35
▸ PTPN5 P54829 1/20 0.35
▸ PTPN11 Q06124 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ENPP3 O14638 1/20 0.33
▸ ALPL P05186 1/20 0.33
▸ XIAP P98170 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30600526 1.00 HCRTR1 (0.38) HCRTR1HCRTR2HTTMAPTSMN1; SMN2
SCHEMBL26675338 0.91 ENPP3 (0.42) HTTMAPTSMN1; SMN2TP53PKM
SCHEMBL26675342 0.89 HCRTR1 (0.40) HCRTR1HCRTR2HTTMAPTSMN1; SMN2
SCHEMBL30600517 0.89 HCRTR1 (0.40) HCRTR1HCRTR2HTTMAPTSMN1; SMN2
SCHEMBL30600513 0.89 MAPT (0.42) HCRTR1HCRTR2HTTMAPTSMN1; SMN2
SCHEMBL26675311 0.89 MAPT (0.42) HCRTR1HCRTR2HTTMAPTSMN1; SMN2
SCHEMBL30600511 0.87 ENPP3 (0.41) HTTMAPTSMN1; SMN2TP53PKM
SCHEMBL26675330 0.87 ENPP3 (0.41) HTTMAPTSMN1; SMN2TP53PKM
SCHEMBL26675349 0.87 ENPP3 (0.41) HTTMAPTSMN1; SMN2TP53PKM
SCHEMBL30600528 0.87 P2RX7 (0.36) HCRTR1HCRTR2HTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US claimed
EP-4284797-A1 PYRAZOLEAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-12-06 — — EP claimed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US claimed
WO-2022162034-A1 PYRAZOLEAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-08-04 — — WO claimed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US disclosed
EP-4284797-A1 PYRAZOLEAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-12-06 — — EP disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
WO-2022162034-A1 PYRAZOLEAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES P2RY1, P2RX1, P2RX5 HCRTR1 972/4885HCRTR2 1503/4885HTT 4269/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B HCRTR1 3185/4885HCRTR2 2462/4885HTT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback